Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Related Citations for PubMed (Select 21406395)

1.

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, Andersen MH.

Cancer Res. 2011 Mar 15;71(6):2038-44. doi: 10.1158/0008-5472.CAN-10-3403.

2.

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Löb S, Königsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G, Terness P.

Cancer Immunol Immunother. 2009 Jan;58(1):153-7. doi: 10.1007/s00262-008-0513-6. Epub 2008 Apr 17.

PMID:
18418598
3.

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K.

Cancer Res. 2009 Jul 1;69(13):5498-504. doi: 10.1158/0008-5472.CAN-08-2106. Epub 2009 Jun 2.

4.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH.

Blood. 2011 Feb 17;117(7):2200-10. doi: 10.1182/blood-2010-06-288498. Epub 2010 Nov 15.

5.

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.

Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W.

Clin Cancer Res. 2007 Dec 1;13(23):6993-7002.

6.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
7.

Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.

Bernhard H, Jäger E, Maeurer MJ, Meyer zum Büschenfelde KH, Knuth A.

Tissue Antigens. 1996 Jul;48(1):22-31.

PMID:
8864171
8.
9.

Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.

Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA.

J Immunol. 2009 Jul 15;183(2):1022-31. doi: 10.4049/jimmunol.0900408. Epub 2009 Jun 29.

10.

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.

Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH.

PLoS One. 2012;7(4):e34568. doi: 10.1371/journal.pone.0034568. Epub 2012 Apr 23.

11.

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.

Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, Mosser J, Quillien V.

J Neuroimmunol. 2010 Aug 25;225(1-2):22-33. doi: 10.1016/j.jneuroim.2010.04.003. Epub 2010 May 20.

PMID:
20493562
12.

Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.

Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S.

J Exp Ther Oncol. 2003 Nov-Dec;3(6):336-45.

PMID:
14678522
13.
14.

Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.

van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.

Eur J Immunol. 1996 Aug;26(8):1683-9.

PMID:
8765006
15.

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.

El Kholy NM, Sallam MM, Ahmed MB, Sallam RM, Asfour IA, Hammouda JA, Habib HZ, Abu-Zahra F.

Med Oncol. 2011 Mar;28(1):270-8. doi: 10.1007/s12032-010-9459-6. Epub 2010 Mar 19.

PMID:
20300979
16.

Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells.

Sun T, Chen XH, Tang ZD, Cai J, Wang XY, Wang SC, Li ZL.

Mol Cell Biochem. 2010 Sep;342(1-2):29-34. doi: 10.1007/s11010-010-0465-y. Epub 2010 Apr 28.

PMID:
20424892
17.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

18.

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.

Austin CJ, Mailu BM, Maghzal GJ, Sanchez-Perez A, Rahlfs S, Zocher K, Yuasa HJ, Arthur JW, Becker K, Stocker R, Hunt NH, Ball HJ.

Amino Acids. 2010 Jul;39(2):565-78. doi: 10.1007/s00726-010-0475-9. Epub 2010 Feb 7.

PMID:
20140689
19.

Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.

Bernhard H, Karbach J, Wölfel T, Busch P, Störkel S, Stöckle M, Wölfel C, Seliger B, Huber C, Meyer zum Büschenfelde KH, et al.

Int J Cancer. 1994 Dec 15;59(6):837-42.

PMID:
7989126
20.

Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.

Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG.

J Immunol. 1993 Oct 15;151(8):4209-20.

PMID:
8409397
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk